# CONCEPT: A 1-Year Comparison Of A Stable Dose Of SERETIDE® Inhaler With An Adjustable Maintenance Dose Of SYMBICORT® Inhaler. SERETIDE® Inhaler is a Trademark of GSK Group of Companies. SYMBICORT® Inhaler is a Trademark of Astra Zeneca.

> **NCT00479739** · PHASE4 · COMPLETED · sponsor: **GlaxoSmithKline** · enrollment: 700 (actual)

## Conditions studied

- Asthma

## Interventions

- **DRUG:** Salmeterol/fluticasone propionate or formoterol/budesonide

## Key facts

- **NCT ID:** NCT00479739
- **Lead sponsor:** GlaxoSmithKline
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2002-11
- **Primary completion:** 2004-07
- **Final completion:** 2004-07
- **Target enrollment:** 700 (ACTUAL)
- **Last updated:** 2016-09-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00479739

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00479739, "CONCEPT: A 1-Year Comparison Of A Stable Dose Of SERETIDE® Inhaler With An Adjustable Maintenance Dose Of SYMBICORT® Inhaler. SERETIDE® Inhaler is a Trademark of GSK Group of Companies. SYMBICORT® Inhaler is a Trademark of Astra Zeneca.". Retrieved via AI Analytics 2026-09-09 from https://api.ai-analytics.org/clinical/NCT00479739. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*